Abbott Climbs, Intuitive Stumbles: Which MedTech Wins?

MedTech investors face a critical decision between Abbott Laboratories and Intuitive Surgical. Abbott, a diversified healthcare company, reported strong second-quarter results across diagnostics, medical devices, and nutrition, leading it to raise its annual profit outlook.

Intuitive Surgical, the dominant player in robotic surgery, also surpassed revenue and earnings expectations. However, its shares declined as investors noted a slowdown in domestic procedure growth. The company's business model heavily relies on recurring revenue generated from its expanding installed base of da Vinci surgical systems.

Abbott's diagnostics division was a standout, with revenue climbing 42% year-over-year to $3.09 billion, bolstered by its cancer diagnostics, including the Cologuard test. This segment now significantly contributes to Abbott's overall performance.

Meanwhile, Intuitive Surgical continues to grow its installed base, placing 468 da Vinci systems in the quarter, an 18% increase. The adoption of its new da Vinci 5 platform is also accelerating, ensuring a consistent stream of future revenue long after initial system sales.